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ABSTRACT
The overall 5-year survival rate for woman diagnosed with breast cancer has
increased significantly over the last 20 years. However, prognosis for women with stage
IV, metastatic disease remains very poor. Women diagnosed with stage 0-III breast
cancer have above an 85% chance of survival over a 5-year period while women
diagnosed with stage IV breast cancer have a 5-year survival of less than 30%. A better
understanding of the molecular mechanisms driving aggressive breast cancer is essential
for the potential discovery of more targeted therapies to increase the survival rates for
women diagnosed with stage IV breast cancer.
Previous members of the Stein/Lian laboratory profiled 113 novel, small RNA
molecules in various breast cancer cell models to identify potential candidates for testing.
In this study, we examine a novel class of short, non-coding RNA molecules called
tRNA-derived small RNAs (tsRNAs). These molecules are 18-48 nucleotides long and
are cleaved RNA fragments generated during tRNA maturation. We identified two
candidate tsRNAs, ts-2 and ts-112, that have relatively low expression in the normal-like
breast epithelial cell line, MCF10A, and increase in expression as breast cancer becomes
more aggressive, with the highest expression in the MCF10CA1a cell line.
Because ts-2 and ts-112 are upregulated in MCF10CA1a cells compared to
MCF10A cells, we hypothesized that ts-2 and ts-112 promote breast cancer disease
progression. In this study, inhibitors of ts-2 and ts-112 were transfected into
MCF10CA1a cells and mimics were transfected into MCF10A cells to further understand
the role of these molecules in certain cancer phenotypes. Assays were performed to
assess the affect of tsRNA on cell growth, death, migration, invasion, and any cell cycle
changes after ts-2 and ts-112 gain or loss of function
We observed a decrease in cell growth rate over time after ts-2 and ts-112
inhibition in MCF10CA1a cells. In trypan blue exclusion growth curve assays, tsRNA
inhibited populations had fewer cells than mock and negative control populations over a
72-hour time course. Further, we observed parallel results with CCK-8 assays for cell
proliferation and in a flow cytometry analysis of the cell cycle. The percent of cells in S
phase increased in the ts-2 and ts-112 inhibited populations when compared to the mock
and negative control, indicating that cells are blocked in S phase after tsRNA inhibition.
We observed an increase in cell growth rate over time after ts-2 and ts-112
overexpression in MCF10A cells. We performed trypan blue exclusion growth curve
assays and saw an increase in population growth over a 72-hour time course. In parallel,
similar results were observed using a CCK-8 cell proliferation assay, where ts-2 and ts112 overexpressed populations had an increase in cell proliferation compared to mock
and negative control. Cell death, migration and invasion were unchanged when ts-2 and
ts-112 levels were manipulated in these cell models.
Our results reveal the role of ts-2 and ts-112 in breast cancer and provide a better
understanding of the molecular mechanisms related to a worsened prognosis for women
with stage IV disease compared to women with stage 0-III disease. Future studies could
potentially lead to the use of tsRNAs as blood biomarkers for cancer risk and diagnosis or
as a target for novel chemotherapies for cancer treatment.
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CHAPTER 1: INTRODUCTION
1.1 Cancer Facts and Statistics
Cancer is defined as the uncontrolled growth of cells with the ability to invade
surrounding tissue (1). According to the American Cancer Society, 1,806,590 new cases
of cancer will be diagnosed in the United States in 2020. As the second leading cause of
death in the country, cancer will take an estimated 606,520 lives this year (1). Although
cancer is common, some tissue types are affected more often than others. Aside from
basal cell carcinoma, a type of skin cancer, men are at the highest risk to develop prostate
cancer (20% of all new cases) and women are at the highest risk to develop breast cancer
(30% of all new cases). In the United States, 1 in 8 women will be diagnosed with breast
cancer at some point in her life (1). In 2020, it is estimated that there will be 276,480 new
cases of breast cancer in the United States, and 42,170 deaths (1).
1.2 Breast Cancer Overview
Breast cancer arises after genetic mutations occur in mammary epithelial cells that
lead to deregulated control of cell growth and tissue homeostasis. While every subtype of
cancer is different, cancer cells often share phenotypic characteristics such as the ability
to evade apoptosis, insensitivity to anti-growth signals, self-sufficiency in growth signals,
sustained angiogenesis, limitless replicative potential and capability of invading
surrounding tissue (2). Cancer cells are often invasive and rapidly dividing. It is
important to identify the presence of cancer and to begin a treatment regimen in a patient
as early as possible to ensure the best outcome.
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Early detection is important for improving outcomes. Early detection often is
associated with limited disease progression which is easier to treat compared to later
stage disease. Regular breast exams, ultrasounds, mammograms, screening magnetic
resonance imaging (MRI) and biopsies are key screening and diagnosis techniques for
breast cancer. According to the National Comprehensive Cancer Network guidelines for
breast cancer screening and diagnosis, every woman age 45 and above is recommended
to have a yearly mammogram. Mammography is X-ray imaging of the breast tissue used
to screen for breast cancer. It has been reported that women who are screened for breast
cancer by mammography have a 60% reduced risk of death caused by the disease over a
10 year period (3). While mammography is often the preferred screening route, some
genetically predisposed, young, premenopausal women have dense breast tissue, which
alters the effectiveness of mammography detection. Often, MRIs are a more sensitive
method of screening, used in this subset of patients who are considered high risk for the
disease (4).
1.3 Staging of Breast Cancer
Breast tumors are categorized into five stages (0-IV). Staging of the cancer allows
both the physician and the patient to understand the prognosis of the disease as well as
informs individual treatment strategy development.
Non-invasive breast cancers are classified as stage 0. Commonly referred to as
carcinoma in situ (CIS), stage 0 breast cancer is defined as a population of abnormal cells
within the breast tissue that have the potential of developing into cancer. CIS can be
further divided into two categories based on tumor location: lobular carcinoma in situ
2

(LCIS) and ductal carcinoma in situ (DCIS). As their names suggest, LCIS originates in
the breast lobules and DCIS originates in ductal system of the breast tissue. As LCIS
rarely progresses to become invasive disease, prophylactic tamoxifen, a selective
estrogen receptor modulator, is recommended for treatment. The National
Comprehensive Cancer Network reports a 4-10x increased risk of developing invasive
breast cancer when LCIS is present (5). Unlike LCIS, DCIS often progresses into
invasive breast cancer (5). DCIS is treated by either lumpectomy or total mastectomy and
reconstruction surgery, according to the most recent National Comprehensive Cancer
Network guidelines. There will be approximately 48,530 new cases of DCIS diagnosed in
American women this year (1).
Stage I and II breast cancer are both considered early-stage, invasive disease.
Typically, stage I tumors are 2 centimeters or less and remain localized to the breast
tissue. Stage II tumors range from 2-5 centimeters in size and also remain localized to the
breast tissue itself (6). Treatment for stage I and II breast cancer typically involves a
combination of breast conserving surgery and radiation therapy (7). Breast conserving
surgery involves the removal of a tumor, but not the healthy breast tissue and is often
referred to as a lumpectomy.
Stage III breast cancer is often described as locally advanced. These tumors are
larger than 5 centimeters and considered inoperable (7). Treatment typically involves
removing all breast tissue in attempt to restrain any current or future cancer growth in the
area, a procedure known as a mastectomy.
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Stage IV breast cancer involves metastasis, which is when cancer cells migrate
and invade surrounding tissue, often into the blood or lymphatic systems. Metastatic
disease has the worst prognosis among all stages. While chemotherapy is used for
treatment of this disease stage, radiation is also used to manage disease-related pain (7).
1.4 Survival Rates Based on Disease Stage
Characterization of a patient’s breast cancer into stages helps determine the
prognosis for each individual. That said, the five-year survival rate for a woman with
breast cancer is determined by the stage of her disease. In the year 2000, the five-year
survival rate for women, black or white, with stage 0 disease was 89-97%, and increased
in the year 2020 to 96-99%. For stage I-II disease, the five-year survival rate for black
and white women was 63-78% in 2000 and has increased to 77-87% in 2020. Stage III
disease had a five-year survival rate of only 14-22% in black and white women in the
year 2000 and has only increased to 20-29% in the year 2020. While the less aggressive
stages have increased survival rates, the five-year survival rate of stage IV disease
remains less than 30% (1, 8). There remains a need for a better understanding of the
molecular mechanisms driving stage IV disease to improve the overall survival rates of
patients diagnosed with aggressive breast cancer.
1.5 Hormone Receptors and Tumor Subtypes
Besides clinical staging, receptors expressed by breast cancer cells allow for
molecular characterization of the cancer. The presence of specialized proteins, namely
estrogen receptor (ER), progesterone receptor (PR), and receptor tyrosine-protein kinase
ERBB-2 (HER2), either inside the cells or on the cell surface, are important in deciding
4

treatment for an individual patient. Knowing what specialized proteins are expressed in
an individual cancer cell population allows targeted treatment with drugs designed to
bind and alter the proteins in order to slow down or kill the cells. While estrogen and
progesterone receptors are proteins located within the cell (9), HER2 is a transmembrane
protein (10). As their names suggest, the ligand for ER is estrogen, the ligand for PR is
progesterone. These hormones enter the cell through simple diffusion in order to bind to
and activate their receptors. The ligand for HER2 is epidermal growth factor (EGF) and
EGF can bind a ligand binding site on the outside of the cell to activate various
downstream effects. Active HER2 leads to activation of STAT, Ras, and Src which are
responsible for cellular functions that promote cancer - like proliferation, differentiation,
and motility. Often in cancer, HER2 is overexpressed and activated independently of
ligand binding (10), which causes downstream effects such as increased growth, which
can help to explain why cancer cells continually grow and divide.
Depending on receptor expression in an individual patient’s cancer, it can be
described as the following: estrogen/progesterone receptor positive (ER/PR+) or
estrogen/progesterone receptor negative (ER/PR-) and receptor tyrosine-protein kinase
ERBB-2 positive (HER2+) or receptor tyrosine-protein kinase ERBB-2 negative (HER2). To determine which hormone receptors are present in an individual patient’s cancer,
immunohistochemistry is performed to specifically stain the receptors of interest. A
cancer is considered ER+ if the immunohistochemistry stains 1-100% of the cells present
in the tested sample. If less than 1% of the cell nuclei are stained, the cancer is considered
ER- (11). If a patient is ER+, endocrine therapy can be used for treatment. Selective
5

endocrine receptor modulators (SERMs), like tamoxifen, are used for treatment of ER+
breast cancer to slow cancer growth and shrink tumors (12). For this reason, ER+ breast
cancer is associated with a more favorable outcome than ER- breast cancer (13). Testing
for the presence of PR is done in the same fashion, but results of this test help determine
prognosis, and not treatment regimen (11). HER2 levels are sometimes increased in
breast cancers, leading to increased growth factor signaling and therefore elevated cancer
cell growth rates. Levels of HER2 on the cell surface should be measured in patients with
breast cancer to determine if they would benefit from treatment with certain monoclonal
antibodies. These antibodies are specifically designed to bind to the growth factor
receptor, resulting in inhibition of HER2 activity, such as slowed cancer cell growth (6).
Further, some patients do not express any hormone receptors, and are considered to have
triple negative breast cancer, which is the most difficult to treat (14).
There are four intrinsic molecular subtypes of breast cancer: luminal A, luminal
B, HER2 enriched, and basal-like. Luminal A is ER/PR+ and HER2-, and luminal B is
ER/PR+ and HER2+/-. These types are determined based on proliferation and luminal
pathways. As their names suggest, proliferation pathways are cell cycle related and
luminal pathways are hormone-regulated pathways. Luminal B tumors express proteins
related to cell cycle regulation at higher levels and have lower expression of progesterone
receptor than Luminal A tumors. HER-2 enriched breast cancers express high levels of
HER-2 and other proliferation-related genes but are ER/PR-. Basal-like breast cancers are
usually ER-/PR-/HER2- and involve high expression of proliferation genes at the basal
layer of the skin (15, 16).
6

1.6 Breast Cancer Cell Models
Despite the knowledge of signaling pathways like those involving ER and HER2,
there remains a lack of understanding of the molecular mechanisms driving aggressive
breast cancer. Cell lines derived from breast tissue isolated from healthy or cancerous
women are well established to model normal-like and tumor cell behavior. Researchers
are better able to relate in vitro studies to in vivo effects by categorizing cell lines based
on the presence of cell surface hormone receptors (17). Commonly studied cell lines
include the MDA-MB-231, MCF7, and MCF10 cell lines. MDA-MB-231 cells are
representative of triple negative breast cancer. MCF7 cells represent a subset of breast
cancers that are ER/PR+ and HER2-. MCF10 cells are an ER low/HER2+ breast cancer
cell model (17). The MCF10 set of cell lines is commonly used to study breast cancer
progression, modeling the normal-like mammary epithelium as well as different stages of
cancer initiation, development, and progression (18). Obtained from subcutaneous
mastectomy tissue of a 36-year old healthy female, the MCF10 cell line was
immortalized into suspension cells, MCF10M, and adherent cells, MC10A. Because of
their adherent nature, MCF10A cells are contact dependent, and therefore similar to
normal mammary epithelial cells. Because of this, MCF10A cells were used for further
transformations. MCF10A cells were transformed with mutated H-RAS followed by
serial xenografts to generate the MCF10AT1 cell line, representing early stage, estrogen
receptor negative breast cancer. The MCF10CA1a was further derived from subsequent
xenograft rounds selecting for aggressive breast cancer cells (18).
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1.7 Noncoding RNA Molecules in Breast Cancer
Studies over the last two decades have established that noncoding RNA molecules
(ncRNAs) are important in the normal development of a cell. Long ncRNAs are over 200
nucleotides long and have established roles in chromatin rearrangement, histone
modification, modification in alternative splicing, and the regulation of gene expression
as well as functions in tumorigenesis (19). Small ncRNAs are shorter than 200
nucleotides and have also been discovered to have a role in promoting cancer initiation
and progression (20). Recently, a novel class of small ncRNA has been identified that
distinguishes normal-like cells from breast cancer cells (20).
1.8 TsRNA Biogenesis and Characteristics

Figure 1.1: TsRNA Biogenesis.
TsRNAs are formed during the maturation of tRNA from pre-tRNA. RNAse P cleaves
the 5’ end first, then RNAse Z cleaves the 3’ end of pre-tRNA and the cleaved, short noncoding RNA fragment known as tsRNA is 18-48 nucleotides in length. Pre-tRNA
structure from Molla-Herman et. al, 2019 (21).
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It has been recently discovered that tRNA-derived small RNA (tsRNA) molecules
are dysregulated in breast cancer. TsRNAs are small, non-coding RNA molecules formed
during the maturation process of tRNA. Pre-tRNA is cleaved in the nucleus or
mitochondria by RNaseP and RNaseZ, enzymes which cleave nucleotides from the 5’
and 3’ end, respectively. Cleavage from the 3’ end by RNaseZ results in a 16-48
nucleotide short, noncoding RNA molecule, known as tsRNA (22). Preliminary studies
on tsRNAs show that while some tsRNAs, like ts-36, promote cancer cell proliferation
(23), others like ts-47, slow it down (24). It has also been reported that tsRNAs are
associated with argonaut proteins and function like microRNAs, a well-studied class of
small ncRNA, in some cancers (25, 26).
When tsRNAs were discovered in the 1970s, it was believed that tsRNA
molecules were simply biproducts of tRNA maturation. However, recent studies have
identified important roles for tsRNA in regulating cellular function, both in healthy and
disease states (22). Cellular functions and biological roles for which tsRNAs are
important include: regulating mRNA stability, inhibiting translation initiation and
elongation, regulating ribosome biogenesis, regulating RNA reverse transcription,
regulating apoptosis, and functioning as a novel epigenetic factor (22). Levels of tsRNAs
are abnormal in various stressful cellular conditions, or disease states, including cancer.
Since tsRNA levels are upregulated in some cancer, it is suggested that they play a
protective role in cell survival. It has been reported that tsRNAs can serve as targets for
tumor therapy as well as detection strategies for cancer diagnosis via patient urine or
serum samples (22).
9

To elucidate the molecular mechanisms driving breast cancer, the Stein/Lian
research group profiled 113 established tsRNA in MCF10A, MCF10AT1, MCF7,
MCF10CA1a, and MDA-MB-231 cell lines and H9 female human embryonic stem cells
(hESC). Two tsRNAs, ts-2 and ts-112, have relatively low levels in the normal-like,
mammary epithelial MCF10A cells and high levels in MCF10CA1a and MDA-MB-231
aggressive breast cancer cell lines (20). Further, H9 hESCs express high levels of ts-2 and
ts-112. Studies have identified many genes highly expressed in hESCs to be upregulated
in cancer cells (20). For this reason, ts-2 and ts-112 were chosen for our studies. Prior
work in our laboratory showed that when t-2 and ts-112 are inhibited in MCF10CA1a
cells, there is a decrease in growth, an increase in death, an increase in cell doubling time,
and an increase in cell motility. Most recently, members of the Stein/Lian laboratory have
reported that ts-112 is selectively responsive to runt-related transcription factor 1
(RUNX1), a tumor suppressive transcription factor in mammary cells. In a recent
publication, it was reported that ts-112 and RUNX1 are anticorrelated, shown through
studies using both a normal model with MCF10A cells and a cancer model using
MCF10CA1a cells. When RUNX1 is overexpressed in MCF10CA1a cells, ts-112 is
downregulated (27). Combined, these data suggest that ts-112 may be oncogenic.
1.9 Hypothesis, Specific Aims and Project Overview
Here, our long-term goal in characterizing this novel class of small non-coding
RNA, tRNA-derived small RNA, is to understand further the molecular mechanisms of
breast cancer initiation, progression, and metastasis. This knowledge could introduce a
potential target for treatment of patients with aggressive breast cancer, in the effort of
10

increasing overall survival rates in patients with this disease. The overall objective of this
study is to continue to examine the role of ts-2 and ts-112 in breast cancer through lossof-function and gain-of-function experiments. Our central hypothesis is that ts-2 and ts112 regulate cell growth, death, migration, and invasive ability to promote aggressive
breast cancer disease progression. The rationale for this project is the unmet need to
improve the survival rate in women diagnosed with stage IV breast cancer by discovering
new treatment approaches. While stage I-III breast cancers have a 85-99% overall 5-year
survival rate, stage IV breast cancer 5-year survival rate is only 27% and has not
significantly improved in the last 20 years (1, 8).
Aim 1 of the project is to identify the functions of ts-2 and ts-112 in aggressive
breast cancer. To improve the rigor of this project and to further assess the role of ts-2
and ts-112 in the metastatic MCF10CA1a cell line, we will compare different custom ts-2
and ts-112 inhibitors with unique mechanisms of action. We will use cell proliferation
(CCK-8) to validate preliminary cell counts over a 72-hour time course of tsRNA
inhibition. In addition, we will test cell migration and invasion using a trans-well assay,
to support our preliminary findings observed from a scratch assay.
Aim 2 is to determine the ability of ts-2 and ts-112 to promote breast cancer
characteristics in the normal mammary epithelium. We will assess cell growth, cell
death, and the migratory abilities of MCF10A cells that have been transfected with
mimics to overexpress ts-2 and ts-112. This approach will allow us to investigate the role
of tsRNA molecules in promoting breast cancer phenotypes. These tests will be done
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using the same assays as described in the ts-2 and ts-112 inhibited MCF10CA1a model
(Aim 1).
The work done to complete this project showed that ts-112 promotes cell
proliferation. In assays using MCF10CA1a cells, ts-112 inhibited populations had a
decrease in growth compared to control groups. In assays using MCF10A cells, the ts112 overexpressed populations had an increase in growth compared to the control groups.
This finding is supportive of our central hypothesis and identifies ts-112 as a potential
molecular target for precision treatment in patients with aggressive breast cancer.
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CHAPTER 2: MATERIALS AND METHODS
2.1: Cells
The cell lines used in these studies include the normal-like breast epithelial cell line,
MCF10A, and an aggressive breast cancer cell line, MCF10CA1a, derived from RAStransformed MCF10A cells. Both cell lines were grown and maintained in base media
containing 50% DMEM and 50% F12 with L-glutamine (Corning, Thermo Fisher
Scientific). Additional nutrients added to make complete media for MCF10A cells as
volume/volume percentage: 5% horse serum (Gibco, Thermo Fisher Scientific), 1%
penicillin G (100 units/mL) and streptomycin (100 μg/mL; Gibco, Thermo Fisher
Scientific), 1% L-glutamine (Thermo Fisher Scientific), 0.1% human insulin (10 μg/mL
final; Sigma-Aldrich), 0.02% human epidermal growth factor (20ng/mL final;
PeproTech), 0.01% cholera toxin (100ng/mL final; Sigma-Aldrich), and 0.05%
hydrocortisone (0.5 μg/mL final; Sigma-Aldrich). Additional nutrients added to the
MCF10CA1a complete media as volume/volume percentage: 5% horse serum (Gibco
Thermo Fisher Scientific) and 1% penicillin G (100 units/mL) and streptomycin (100
μg/mL; Gibco, Thermo Fisher Scientific). Stock cells were maintained in 100 mm plastic
tissue culture treated dishes (Corning, Thermo Fisher Scientific) at densities ranging from
0.5x106 – 10x106 and 10 mL of media was renewed every 1-2 days.
2.2: Inhibitors
•

Custom miRIDIAN hairpin inhibitors of ts-2 and ts-112 and a negative control
inhibitor were purchased from Dharmacon (Horizon Discovery).
o Sequences:
▪ ts-2: 5’ – UGCAGCACGCCCUCCCAUUUUGGUG – 3’
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▪
▪
•

ts-112: 5’ - CUCGGCUUUCCCUGCUAACUGGGCUUU - 3’
Negative Control: 5’ – UCACAACCUCCUAGAAAGAGUAGA
– 3’

Single stranded mirVana miRNA oligonucleotides designed to bind and inhibit ts2 and ts-112 as well as a negative control inhibitor were purchased from Ambion
(Invitrogen, Thermo Fisher Scientific).
o Sequences:
▪ Ts-2: 5’ – AAAUGGGAGGGCGUGc – 3’
▪ Ts-112: 5’ - AGCCCAGUUAGCAGGGAAAGCCGAGTT - 3’
▪ Negative Control: mirVana™ miRNA Inhibitor, Negative Control
#1

•

Complexes were purchased from Qiagen, made to specifically inhibit ts-2 and ts112.
o Sequence:
▪ Ts-2: 5’ – AAATGGGAGGGCGTG – 3’
▪ Ts-112: 5’ – AGTTAGCAGGGAAAGCCGA – 3’
▪ Negative Control: 5’ – TAACACGTCTATACGCCCA*/36-FAM/
– 3’
2.3: Mimics

Custom mirVana miRNA mimics of ts-2 and ts-112 that are small, chemically modified
double-stranded RNA molecules were purchased from Ambion (Invitrogen, Thermo
Fisher Scientific).
Sequences:
Ts-2: 5’ – AUGGGAGGGCGUGCTT – 3’
Ts-112: 5’ - AGCCCAGUUAGCAGGGAAAGCCGAGTT - 3’
Negative Control: mirVana™ miRNA Mimic, Negative Control #1
2.4 Transfection
Lipofectamine 3000 (Invitrogen, Thermo Fisher Scientific) was used as the transfection
reagent for all transfections throughout this project. Cells were plated 24 hours prior to
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transfection, which allowed time for cells to adhere to the plate and grow to be 70-90%
confluent at the time of transfection. Conditions for 6-well plates (CytoOne Multiple
Well Plates, USA Scientific) were 7.5 µL mimic/inhibitor, 5 µL P3000 reagent, and 7.5
µL of Lipofectamine 3000 reagent. Conditions for 100mm dish (Corning, Thermo Fisher
Scientific) were 25 µL mimic/inhibitor, 28 µL P3000 reagent, and 43 µL of
Lipofectamine 3000 reagent. Prior to adding to cells, Lipofectamine 3000 reagent was
combined with base DMEM/F-12 50/50 incomplete media (Corning, Thermo Fisher
Scientific) and mixed well. A second master mix of mimic/inhibitor and P3000 reagent
was made in base DMEM/F-12 50/50 incomplete media. The two master mixes were
combined in a 1:1 ratio and incubated for 20 minutes to allow nucleic acid/lipofectamine
complexes to form. An appropriate volume of transfection complexes (XX for 6WP, XX
for 100mm) were added to pre-plated adhered cells in complete media and incubated at
37°C for desired transfection time period (4 or 24 hours).
2.5: Growth Curves
5x106 viable MCF10CA1a cells, based on Trypan blue exclusion (Invitrogen, Thermo
Fisher Scientific) count, were plated in 100 mm plastic tissue culture treated dishes
(Corning, Thermo Fisher Scientific) with 10 mL complete media and allowed to adhere to
the dish and grow for 24 hours. Cells were transfected with 50 nM inhibitor (Dharmacon,
Horizon Discovery) or 25 nM inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific)
using Lipofectamine 3000 for 24 hours. Parallel controls included mock treatment (no
nucleic acid) and appropriate negative control inhibitor. After incubation, cells of each
condition were plated into wells of a 6-well plate (CytoOne Multiple Well Plates, USA
18

Scientific) at 5x104 cells/well with 2 mL complete media in triplicate wells. Cell counts
were determined using trypan blue exclusion (10 µL cells in media and 10 µL trypan
blue) (Invitrogen, Thermo Fisher Scientific) on a Countess II FL (Life Technologies,
Thermo Fisher Scientific) automated cell counter 24, 48, and 72 hours after plating.
2.6: Cell Counting Kit-8
MCF10CA1a cells were plated in a single well of a 6-well plate (CytoOne Multiple Well
Plates, USA Scientific) at viable cell counts of 0.5x106 and allowed time (24 hours) to
adhere to the plate and grow. Cells were transfected with 50 nM inhibitor (Dharmacon,
Horizon Discovery) or 25 nM inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific)
using Lipofectamine 3000 for 4 hours. Parallel controls included mock treatment (no
nucleic acid) and appropriate negative control inhibitor. The same procedure was
performed for MCF10A cells using 25 nM mimics (Ambion, Invitrogen, Thermo Fisher
Scientific). After the 4 hour incubation with transfection complexes, cells of each
condition were plated in triplicates per condition in 96-well flat bottom plates (Costar,
Corning, Thermo Fisher Scientific) at 5,000 cells in 100 µL of complete media. 10 µL of
WST-8 tetrazolium salt (Abcam) was added to each well at appropriate time points (0,
24, 48, 72 hours post-plating) and allowed to incubate for 3 hours. Cell viability was
assessed using a Victor X4 (Perkin Elmer, Inc.) plate reader at an absorbance of 450 nm.
Background (complete media + WST-8) was subtracted from absorbance readings in
order to ensure readings were based on cell counts exclusively.
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2.7: Flow Cytometry
For cell cycle analysis, cells were harvested after 24-hour transfection with Dharmacon
inhibitors and fixed in 100% cold EtOH, added dropwise, mixing well. A Cell Cycle Kit
(BD Biosciences) was used by manufacturer’s instructions. Unstained and stained cells
were profiled in the UVM Flow Core by Roxanna Del Rio Guerra. Cell cycle was
modeled in FlowJo (Treestar) and Modfit (Verity Software) based on DNA content.
2.8: Trans-well Assay
MCF10A and MCF10CA1a cells were plated in 100 mm plastic tissue culture treated
dishes (Corning, Thermo Fisher Scientific) 24 hours prior to transfection with 25 nM of
mimic or inhibitor (Ambion, Invitrogen, Thermo Fisher Scientific) for 4 hours.
Corning™ BioCoat™ Matrigel™ Invasion Chambers with or without a GFR Matrigel
matrix coating (Thermo Fisher Scientific) were warmed to room temperature and
rehydrated using warm, serum-free media and incubated at 37°C for 2 hours. After 4
hours of transfection incubation, 50,000 cells were plated into invasion chambers (lined
with GFR Matrigel) or migration chambers (control, no lining) containing serum-free
media. Cells were allowed to invade/migrate through the gel chambers and into fullserum media for 24 hours. Cells were fixed with methanol and stained with crystal violet
stain for imaging on an inverted microscope.
2.9: RNA Isolation
To prepare for isolation of RNA after transfection with mimic or inhibitors, cells were
lysed with QIAzol reagent and transferred into a 1.5 mL tube (Eppendorf). Chloroform
was added to separate the RNA layer from other cellular components. Ethanol was added
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and samples were passed through a spin column (Qiagen) for filtration. After addition of
various buffers, columns were spun, and flow through was discarded per manufacturer
guidelines (miRNeasy Mini Kit, Qiagen), including a DNase digestion and isolated RNA
was stored at -80°C.
2.10: cDNA Synthesis
RNA samples were thawed and 1.5 µL of each sample was analyzed on a Nanodrop 2000
Spectrophotometer (Thermo Fisher Scientific), which quantified the RNA concentration
for each sample. Samples were diluted using RNase free water to a uniform concentration
of 500 ng/µL. Reverse transcriptase (RT) master mix was prepared using 4 µL of 5X
miScript HiSpec buffer (Qiagen), 2 µL of 10X miScript Nucleics mix (Qiagen), 2 µL of
RNase-free water, and 2 µL of miScript reverse transcriptase mix per reaction (Qiagen).
Samples, including a sample without reverse transcriptase master mix, were combined
with this RT mastermix, briefly vortexed and spun for mixing, and cDNA was
synthesized using a C1000 touch Thermal Cycler machine (Bio-Rad Laboratories) using
the following protocol: 1 cycle of 60 minutes at 37°C, 5 minutes at 95°C, and held at 4°C
until storage at -20°C.
2.11: Primer Sequences
Specific forward primers and the Universal Reverse Primer used for qPCR analysis were
purchased from Invitrogen (Thermo Fisher Scientific).
▪

Sequences:
o U6 (control): 5’ – AGCCAAATTCGTGAAGCGTTCCATATT – 3’
o Ts-2: 5’ – TGCAGCACGCCCTCCCATTTT – 3’
o Ts-112: 5’ – AAAGCCCAGTTAGCAGGGAAAGCCGAG – 3’
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2.12: Quantitative Polymerase Chain Reaction (qPCR)
qPCR was performed using miScript qPCR with QuantiTect SYBR Green (Qiagen). Each
well of a 96-well flat bottom plate (Costar, Corning, Thermo Fisher Scientific) contained:
10 µL of 2x QuantiTect SYBR green PCR master mix, 2 µL of 10 uM miRNA/tsRNA
specific forward primer, 2 µL of 10 uM Universal Reverse primer, 2 µL of diluted
cDNA, and 4 µL of RNase-free water. The 96-well flat bottom plate (Costar, Corning,
Thermo Fisher Scientific) was loaded into and run on a ViiA7 qPCR machine using the
following protocol: 15 minutes at 95°C, followed by 40 cycles of 15 seconds at 94°C
(melt), 30 seconds at 55°C (anneal), and 30 second at 70°C (elongate), followed by a
melt curve.
2.13: Statistics
Excel (Microsoft) and Prism 8 (GraphPad) were used for data entry and visualization.
Statistics were calculated using Excel (Microsoft) to generate two tailed, homoscedastic
t-tests of mock or negative control versus the test populations. The p-values to identify
statistical significance is described within each figure legend. Error bars are made using
standard error of the mean.
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CHAPTER 3: RESULTS
Aim 1: Identify the functions of ts-2 or ts-112 in aggressive breast cancer.
To improve the rigor of this project and to further assess the role of ts-2 or ts-112
in the metastatic MCF10CA1a cell line, we compared custom ts-2 or ts-112 inhibitors
with unique mechanisms of action that were purchased from three different companies.
We monitored cell proliferation over a 72-hour time course (trypan blue exclusion, CCK8) to validate preliminary cell count data suggesting tsRNA inhibition slows cell growth
rate over time. Changes in cell cycle distribution were observed using flow cytometry. In
addition, we tested cell migration and invasion using a trans-well assay to support
preliminary scratch assay findings that ts-112 inhibition increases wound healing.
3.1: Dharmacon miRIDIAN hairpin inhibitors against ts-2 or ts-112 reduce
MCF10CA1a cell number over time
To evaluate how ts-2 or ts-112 are involved in regulating cancer cell growth,
MCF10CA1a cells were transfected with Dharmacon miRIDIAN hairpin inhibitors using
the Lipofectamine 3000 transfection reagent. The miRIDIAN inhibitor is composed of
modified RNA with a single-stranded RNA-targeting region bookended by hairpins for
stability. miRIDIAN inhibitors (50 nM) with complementary sequences to ts-2 or ts-112,
or a negative control inhibitor tagged with fluorescent dye to confirm transfection
efficiency, were transfected into 5x106 viable MCF10CA1a cells. A mock control with no
nucleic acid was included. After 24-hours, cells were plated at 5x104 cells/well in
triplicate in 6-well plates and then counted on a Countess II using trypan blue exclusion
24, 48, and 72 hours after plating to identify live and dead cells.
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Phase-bright, trypan blue negative (viable) cell counts from three independent
experiments were plotted over time (Figure 3.1). At 72 hours, the number of
MCF10CA1a cells transfected with either ts-2 or ts-112 inhibitor were reduced as
compared to mock and negative control. On average, inhibition of ts-112 or ts-2 resulted
in an approximate 10% or 15% decrease in population size, respectively, suggesting a
reduction in growth rate. These differences did not reach statistical significance (Tables
3.1-3.3). However, the ts-112 inhibited population showed a suggestive decrease in cell
count (p = 0.093) at 24 hours when compared to either the mock or negative control
cells/groups (see † in Tables 3.1-3.3). Further, MCF10CA1a cells with ts-2 or ts-112
inhibited, shown in blue and red respectively on the graph (Figure 3.1), have an apparent
decrease in growth rate over time between 48 and 72 hours. Although this decrease is not
statistically significant, a shallower slope of the line on the figure suggests that there is a
decrease in population doubling time. Combined, these data suggest that ts-2 or ts-112
could be involved in promoting cell proliferation in aggressive breast cancer.
3.2: Inhibitors of ts-112 may decrease MCF10CA1a cell proliferation rate
To confirm our observation that ts-2 or ts-112 inhibition leads to slower growth,
we performed a different cell proliferation assay (CCK-8) with Dharmacon miRIDIAN
inhibitors and introduced a new set of tsRNA inhibitors, Ambion mirVana antisense
oligonucleotides. Cell proliferation was observed using absorbance readings following a
Cell Counting Kit-8 assay. MCF10CA1a cell groups for this experiment were transfected
using Lipofectaine 3000 for 4 hours in attempt to observe the early decrease in growth
seen in the Dharmacon miRIDIAN Inhibitor Growth Curves
24

miRIDIAN Inhibitor Growth Curve

Live Cell Number

1×10 6

Mock
Negative Control

8×10 5

ts-2 inhibitor

6×10 5

ts-112 inhibitor

4×10 5

†

2×10 5
0
0

24

48

72

Time (Hours)
Figure 3.1: Ts-2 or ts-112 inhibition with miRIDIAN inhibitors may lead to slower
growth of MCF10CA1a cells.
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour
intervals for 72 hours following ts-2 or ts-112 inhibition using Dharmacon miRIDIAN
custom hairpin inhibitors. Cell count of the ts-112 inhibited population was suggestive (p
< 0.1) to be decreased as compared to the mock population at 24 hours after plating. The
slope of both the ts-2 or ts-112 populations suggest slowed growth over time compared to
the control populations between the 48- and 72-hour time points, although the change
was not significant compared to control populations. Error bars represent the SEM of 3
independent experiments performed in triplicate. † p < 0.1.
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Table 3.1: Normalized Experimental Mean Live MCF10CA1a Cell Counts
Time
Mock
Negative Control
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
24
48
72

50,000
58,633
179,667
750,667

50,000
80,233
209,000
731,000

50,000
40,233
198,667
713,333

50,000
41,033
199,333
664,667

50,000
64,500
148,333
512,000

50,000
63,133
145,000
980,333

Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
50,000
50,000
50,000
50,000
50,000
50,000
24
82,100
54,733
56,100
41,067
21,500
31,867
48
256,000
193,667
167,000
144,567
244,333
200,000
72
678,333
408,333
614,000
375,333
587,000
846,667
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count
values are experiment mean of triplicate wells.
Table 3.2: Mean and Standard Error of the Mean (SEM) of 3 Experiments
Time
Mock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
50,000
0
50,000
0
24
59,700
11,559
56,222
7,605
48
195,778
8,590
164,222
17,582
72
731,667
10,782
719,000
137,899
Time
(Hours)

Ts-2 Inhibitor
Ts-112 Inhibitor
Mean
SEM
Mean
SEM
0
50,000
0
50,000
0
24
64,311
8,903
31,478
5,652
48
205,556
26,371
196,300
28,859
72
566,889
81,424
603,000
136,297
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.3: Two-tailed, homoscedastic t-test
Time
(Hours)

Mock vs.
Negative
Control

24
48
72
† p < 0.1

0.814
0.182
0.931

Mock vs. ts- Mock vs. ts2 Inhibitor 112 Inhibitor

0.768
0.74
0.115

0.093†
0.987
0.400
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Negative
Control vs.
ts-2
Inhibitor
0.528
0.262
0.396

Negative
Control vs.
ts-112
Inhibitor
0.059†
0.396
0.582

performed previously. First, the absorbance at 450 nm of mock (no nucleic acid) and
negative control (tagged with fluorescent dye to confirm transfection efficiency) groups
were compared to the populations of cells transfected with 50 nM Dharmacon
miRIDIAN, double stranded, complementary inhibitors with hairpin bookends of ts-2 or
ts-112. After transfection incubation, cells were plated at 5x103 cells/well in 96-well
plates in triplicate per condition. At appropriate time points after plating (0-hours, 24hours, 48-hours, and 72-hours), WST-8 tetrazolium salt reagent was added for 3 hours
and cell proliferation was assessed on a Victor X4 plate reader at absorbance 450 nm.
Numbers reported below (Tables 3.4-3.6) have been normalized to eliminate background
and represent averages of triplicate wells per experiment. Mean and SEM have been
reported and used to generate the graph. A two-tailed, homoscedastic t-test suggests that
the ts-112 inhibited population has a slower proliferation rate compared to the mock
population (p < 0.1) at the 72-hour time point (Figure 3.2A). While the mean absorbance
value of the 72-hour time point for the ts-112 inhibited population is 1.289, the other 3
cell populations have an absorbance value of around 1.4 for that time point. This result
agrees with our hypothesis and with the trypan blue exclusion result, further showing that
ts-112 promotes cell growth.
In attempt to increase confidence in our findings, MCF10CA1a cells were
transfected, using Lipofectamine 3000, with 25 nM Ambion mirVana inhibitors for the
CCK-8 proliferation assay. Here 25 nM inhibitor was used instead of 50 nM due to a
calculation error. Using parallel methods to the Dharmacon miRIDIAN CCK-8 assay,
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A.

miRIDIAN Inhibitors CCK-8 Assay
Absorbance at 450 nm

2.0

Mock
†

Negative Control

1.5

ts-2 inhibitor
ts-112 inhibitor

1.0
0.5
0.0
0

24

48

72

Time (Hours)

mirVana Inhibitors CCK-8 Assay

B.
Absorbance at 450 nm

2.0

Mock
Negative Control

1.5

*
1.0

ts-2 inhibitor
ts-112 inhibitor

*

0.5
0.0
0

24

48

72

Time (Hours)

Figure 3.2: Inhibition of ts-112 may lead to decrease in MCF10CA1a cell
proliferation.
A. CCK-8 assay for cell proliferation is performed by measuring absorbance (OD 450
nm) of MCF10CA1a cells following 4-hour inhibition of ts-2 or ts-112. Absorbance
values are representative of viable cells. A suggestive (p < 0.1) reduction in OD 450 nm
was observed in the ts-112 inhibited population at 72-hours after plating as compared to
the mock population. Error bars represent the SEM of 3 independent experiments
performed in triplicate. † p < 0.1. B. CCK-8 assay for cell proliferation is performed by
measuring absorbance (OD 450 nm) of MCF10CA1a cells following 4-hour inhibition of
ts-2 or ts-112. Absorbance values are representative of viable cells. At both 48- and 72hours following a 4-hour transfection with inhibitor Viable cell count is decreased
significantly (p < 0.05). Error bars represent the SEM of 3 independent experiments
performed in triplicate. * p < 0.05.
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Table 3.4: Absorbance (OD 450 nm)
Time
Mock
(Hours)
Expt. 1
Expt. 2
0
0.046
0.132
24
0.208
0.388
48
0.476
1.056
72
1.315
1.438
Time
(Hours)

Expt. 3
0.105
0.521
1.408
1.391

Ts-2 Inhibitor

Expt. 1
0.121
0.319
0.747
1.478

Negative Control
Expt. 2
Expt. 3
0.071
0.039
0.312
0.211
0.899
0.543
1.443
1.293
Ts-112 Inhibitor

Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
0.092
0.119
0.087
0.126
0.036
0.187
24
0.251
0.513
0.361
0.282
0.237
0.645
48
0.608
1.237
0.889
0.643
0.582
1.499
72
1.381
1.517
1.379
1.282
1.299
1.287
Absorbance values read at OD 450 nm have been normalized to wells with only media
and WST-8 to eliminate background. Values reported represent the background
corrected mean of triplicate wells per experiment.
Table 3.5: Mean and Standard Error of the Mean of 3 Experiments
Time
Mock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
0.094
0.025
0.077
0.024
24
0.372
0.091
0.281
0.035
48
0.980
0.272
0.730
0.103
72
1.381
0.036
1.405
0.057
Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Mean
SEM
Mean
SEM
0
0.099
0.010
0.116
0.044
24
0.375
0.076
0.388
0.129
48
0.911
0.182
0.908
0.296
72
1.426
0.046
1.289
0.005
Mean and SEM of 3 independent experiments performed in triplicates.
Table 3.6: Two-tailed, homoscedastic t-test
Time
Mock vs.
Mock vs. ts- Mock vs. tsNegative
Negative
(Hours)
Negative
2 Inhibitor
112
Control vs.
Control vs.
Control
Inhibitor
ts-2
ts-112
Inhibitor
Inhibitor
0
0.645
0.863
0.687
0.436
0.475
24
0.399
0.983
0.926
0.322
0.467
48
0.438
0.844
0.867
0.434
0.600
72
0.746
0.488
0.064†
0.787
0.113
† p < 0.1
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Table 3.7: Absorbance (OD 450 nm)
Time
Mock
(Hours)
Expt. 1
Expt. 2
0
0.100
0.053
24
0.290
0.254
48
0.809
0.843
72
1.479
1.432

Expt. 3
0.138
0.547
1.291
1.374

Negative Control
Expt. 1
Expt. 2
Expt. 3
0.098
0.080
0.069
0.258
0.356
0.320
0.728
1.107
0.922
1.469
1.494
1.532

Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
0.112
0.073
0.037
0.026
0.039
0.034
24
0.235
0.306
0.241
0.122
0.215
0.164
48
0.807
0.956
0.709
0.488
0.626
0.381
72
1.481
1.494
1.445
1.049
1.257
0.975
Absorbance values read at OD 450 nm have been normalized values to wells with only
media and WST-8 to eliminate background. Values reported represent the background
corrected mean of triplicate wells per experiment.
Table 3.8: Mean and Standard Error of the Mean of 3 Experiments
Time
(Hours)
0
24
48
72

Mock
Mean
0.097
0.364
0.981
1.428

SEM
0.025
0.092
0.155
0.030

Negative Control
Mean
SEM
0.082
0.008
0.311
0.029
0.919
0.109
1.498
0.018

Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Mean
SEM
Mean
SEM
0
0.074
0.022
0.033
0.004
24
0.260
0.023
0,167
0.027
48
0.824
0.072
0.498
0.071
72
1.473
0.015
1.094
0.084
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.9: Two-tailed, homoscedastic t-test
Time
Mock vs.
Mock vs.
Mock vs.
Negative
Negative
(Hours)
Negative
ts-2
ts-112
Control vs.
Control vs.
Control
Inhibitor
Inhibitor
ts-2
ts-112
Inhibitor
Inhibitor
0
0.603
0.521
0.062†
0.738
0.006**
24
0.617
0.339
0.110
0.238
0.021*
48
0.761
0.411
0.047*
0.508
0.032*
72
0.120
0.253
0.020*
0.347
0.009**
† p < 0.1, * p < 0.05, ** p < 0.01
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cells were transfected for 4-hours with mock (no nucleic acid), negative control, single
stranded oligonucleotide inhibitors of ts-2 or ts-112. Following transfection incubation,
cells were plated at 5,000 cells/well in 96-well plates. At appropriate time points after
plating (at 24-hour increments from 0-72 hours), WST-8 reagent was added and
absorbance was read 3 hours later at 450 nm.
Using Ambion mirVana inhibitors, cell proliferation of the ts-112 inhibited
population of cells decreased about 50% compared to the mock population at the 48- and
72-hour time points (Tables 3.7-3.9, Figure 3.2B). Again, a potential for seeing different
results for the same experiment (CCK-8) within the same cell line could be explained by
the fact that the Dharmacon miRIDIAN inhibitors and the Ambion mirVana inhibitors are
working to inhibit the tsRNA molecules of interest by different mechanisms. For the
CCK-8 assays, both inhibitors reflected a decrease in cell proliferation in the ts-112
inhibited population when compared to the mock, with the Ambion mirVana inhibitor
assay showing statistical decrease in cell proliferation. These results were seen using half
the concentration of Ambion mirVana inhibitors than was used for the Dharmacon
miRIDIAN inhibitor assays.
3.3: Ambion mirVana antisense oligonucleotide inhibitors against ts-2 or ts-112 do
not change MCF10CA1a cell counts over time
To determine if 25 nM Ambion mirVana inhibitor could replicate the results seen
following a trypan blue exclusion growth curve with 50 nM Dharmacon miRIDIAN
inhibitors, we performed the experiment with Ambion mirVana inhibitors of ts-2 or ts112. Control groups include mock (no nucleic acid) and negative control. Single-stranded
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antisense oligonucleotide inhibitors against ts-2 or ts-112 were transfected at 25 nM
concentration into the MCF10CA1a cells using the Lipofectamine 3000 transfection
reagent. The experiment was performed as with the Dharmacon miRIDIAN inhibitors
described above. While the miRIDIAN inhibitors showed a potential decrease in
population growth over time of the tsRNA inhibited populations, the mirVana inhibitors
showed no difference between test groups and control groups (Figure 3.3). At each time
point throughout the experiment, the mock, negative control, ts-2 inhibited, and ts-112
inhibited populations were growing at the same rate (Table 3.10-3.12). Varying results
between the two inhibitor types could be explained by the fact that the two inhibitors are
working different ways. While the miRIDIAN inhibitors sequester the tsRNAs using
hairpin loops, the mirVana inhibitors are oligonucleotides designed to bind to the tsRNAs
of interest.
3.4: Inhibition of ts-2 or ts-112 in MCF10CA1a cells increased percent of population
in S phase of the cell cycle
To further investigate changes in MCF10CA1a cell growth following ts-2 or ts112 inhibition, we performed cell cycle analysis after a 24-hour transfection with 50nM
Dharmacon miRIDIAN inhibitors using flow cytometry. Here, we observed an increase
in cells in S phase, and a decrease in G1 phase in the ts-2 or ts-112 inhibited populations
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mirVana Inhibitor Growth Curve
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Figure 3.3: Inhibition of ts-2 or ts-112 in MCF10CA1a cells with mirVana inhibitors
does not change cell growth rate.
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour
intervals for 72 hours following ts-2 or ts-112 inhibition using Ambion mirVana singlestranded oligonucleotide inhibitors. Ts-2 or ts-112 inhibited populations appear to have
an increase in growth rate, especially between 48- and 72-hours after a 24-hour
transfection, although there are no significant differences between control and test
populations. Error bars represent the SEM of 3 independent experiments performed in
triplicate.
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Table 3.10: Normalized Experimental Mean Live MCF10CA1a Cell Counts
Time
Mock
Negative Control
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
50,000
50,000
50,000
50,000
50,000
50,000
24
37,700
67,233
34,800
37,767
37,533
24,433
48
125,333
120,633
99,333
86,300
187,667
106,433
72
635,333
512,333
545,500
623,667
408,287
658,666
Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
50,000
50,000
50,000
50,000
50,000
50,000
24
28,933
44,967
36,566
37,733
43,366
21,100
48
97,433
236,667
94,800
97,833
214,000
74,866
72
692,000
534,333
617,666
764,333
606,000
664,666
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count
values are the mean of triplicate wells.
Table 3.11: Mean and Standard Error of the Mean of 3 experiments
Time
M ock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
50,000
0
50,000
0
24
46,578
10,362
33,244
4,406
48
115,100
7,999
126,800
30,983
72
564,389
36,742
563,540
78,281
Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Mean
SEM
Mean
SEM
0
50,000
0
50000
0
24
36,822
4,630
34,067
6,684
48
142,967
46,856
128,900
43,063
72
614,667
45,539
678,333
46,215
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.12: Two-tailed, homoscedastic t-test
Time
Mock vs.
Mock vs. ts- Mock vs. tsNegative
Negative
(Hours)
Negative
2 Inhibitor
112
Control vs.
Control vs.
Control
Inhibitor
ts-2
ts-112
Inhibitor
Inhibitor
24
0.302
0.438
0.368
0.606
0.923
48
0.733
0.589
0.768
0.788
0.970
72
0.993
0.439
0.126
0.603
0.275
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when compared to the mock and negative control populations (Figure 3.4, Tables 3.133.15). Since the S phase of the cell cycle is defined by DNA synthesis, the increase in the
percent of cells in the population being in this phase of the cell cycle could help explain
why we saw an increase in cell number in the trypan blue experiments and an increase in
cell proliferation in the CCK-8 assays. An increase in S phase may indicate that the cells
are blocked in S phase.
3.5: Inhibition of ts-2 or ts-112 in MCF10CA1a cells does not significantly affect cell
death rates
Cancer cells have the inherent ability to avoid death signals and evade apoptosis.
To assess whether ts-2 or ts-112 are regulators of this characteristic of cancer, we used
the cell death percentages read by the Countess II during the trypan blue exclusion
growth curves. No more than 5% cell death over the 72- hour time course was observed
in any experimental condition (Figure 3.5, Table 3.16-3.18). It is common to see cell
death ≤ 5% in MCF10CA1a cells, even in a stock plate growing with no transfection and
ample nutrients. Thus, there is no effect on cell death when ts-2 or ts-112 are inhibited
using miRIDIAN inhibitors in MCF10CA1a cells. We saw a parallel result in a trypan
blue exclusion growth curve after treatment with Ambion mirVana inhibitors (data not
shown). Further, in an ApoTox-Glo cell death assay using Annexin V, no population of
cells -- control, ts-2 inhibited, or ts-112 inhibited -- had more cell death than another.
There was no increase in the sub-G1 phase when we performed flow cytometry analysis
of the cell cycle (Figure 3.4).
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Figure 3.4: There is an apparent increase in S phase and decrease in G1 phase
following MCF10CA1a inhibition of ts-2 or ts-112 with Dharmacon miRIDIAN
inhibitors. Flow cytometry analysis was performed following a 24-hour Dharmacon
miRIDIAN inhibition of ts-2 or ts-112 in MCF10CA1a cells. Although it does not reach
statistical significance, there is an apparent decrease in S phase, and a decrease in GI
phase of the cell populations with either ts-2 or ts-112 inhibited compared to the mock
population. A. Stacked bar graph of population percentage in each phase of the cell cycle.
B-E. Pie charts including average population percentages in each phase of the cell cycle.
F-I. Histograms with X-axis of 7-AAD-A overlaid with Dean-Jett-Fox model.
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Table 3.13: Population Percentage by Stage
Phase
Mock
Expt. 1
Expt. 2
Expt. 3
G1
77.95%
73.99%
72.83%
S
17.78%
18.60%
8.94%
G2
4.27%
7.40%
18.23%

Expt. 1
76.59%
19.59%
3.82%

Negative Control
Expt. 2
Expt. 3
71.62%
69.63%
19.33%
8.48%
9.05%
21.88%

Phase

Ts-2 Inhibitor
Ts-112 Inhibitor
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
G1
73.86%
70.30%
69.54%
74.31%
69.94%
62.57%
S
21.61%
22.91%
11.99%
13.60%
22.57%
21.34%
G2
4.53%
6.79%
18.47%
12.08%
7.49%
16.10%
Percentages normalized to 100%
Table 3.14: Mean and Standard Error of the Mean of 3 experiments
Phase
Mock
Negative Control
Mean
SEM
Mean
SEM
G1
74.93%
1.55
72.62%
2.07
S
15.12%
3.09
15.80%
3.66
G2
9.96%
4.23
11.58%
5.37
Phase

Ts-2 Inhibitor
Ts-112 Inhibitor
Mean
SEM
Mean
SEM
G1
71.23%
1.33
68.94%
3.43
S
18.84%
3.45
19.17%
2.81
G2
9.93%
4.32
11.89%
2.49
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.15: Two-tailed, homoscedastic t-test
Phase
Mock vs.
Mock vs. ts- Mock vs. tsNegative
Negative
Negative
2 Inhibitor
112
Control vs.
Control vs.
Control
Inhibitor
ts-2
ts-112
Inhibitor
Inhibitor
G1
0.422
0.145
0.187
0.604
0.604
S
0.892
0.466
0.386
0.578
0.578
G2
0.824
0.996
0.715
0.822
0.822
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Cell Death Following miRIDIAN Inhibition
Dead Cell Count/Total
Cell Count (%)

20

Mock
Negative Control

15

ts-2 inhibitor
ts-112 inhibitor

10
5
0
0

24

48

72

Time (Hours)

Figure 3.5: Inhibition of ts-2 or ts-112 with miRIDIAN inhibitors has no effect on
cell death.
Cell death percentages were reported by the Countess II machine during a 72-hour trypan
blue exclusion growth curves of MCF10CA1a cells following 24 hour inhibition with
Dharmacon miRIDIAN inhibitors. Death percentages from 3 independent experiments
averaged less than 5% throughout each population of cells. There is no significant effect
on cell death when ts-2 or ts-112 were inhibited.
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Table 3.16: Normalized Experimental Mean Dead MCF10CA1a Cell Percentages
Time
Mock
Negative Control
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
24
48
72

0.00%
0.00%
0.04%
3.00%

0.00%
16.00%×
0.03%
2.00%

0.00%
1.33%
0.02%
2.66%

0.01%
3.33%
4.00%
1.33%

0.00%
11.33%×
4.00%
2.33%

0.00%
3.67%
2.00%
1.33%

Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
24
0.00%
21.33%×
0.04%
0.00%
56.67%×
2.67%
48
4.67%
3.00%
2.67%
6.67%
3.00%
3.00%
72
1.67%
3.00%
2.33%
0.50%
2.00%
2.67%
Cell death percentages were generated using trypan blue exclusion on a Life
Technologies Countess II FL machine 24, 48, and 72 hours from plating 50,000 live cells.
Reported cell count values are experiment mean of triplicate wells. Cells marked with ×
were omitted outliers.
Table 3.17: Mean and Standard Error of the Mean (SEM) of 3 Experiments
Time
Mock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
0.00%
0.00
0.00%
0.00
24
0.67%
0.94
3.50%
0.23
48
0.03%
0.01
3.33%
1.15
72
2.56%
0.51
1.67%
0.58
Time
Ts-2 Inhibitor
Ts-112 Inhibitor
(Hours)
Mean
SEM
Mean
SEM
0
0.00%
0.00
0.00%
0.00
24
0.02%
0.03
1.33%
1.89
48
2.56%
2.35
4.22%
2.12
72
2.33%
0.67
1.72%
1.11
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.18: Two-tailed, homoscedastic t-test
Time
(Hours)

Mock vs.
Negative
Control

Mock vs.
ts-2
Inhibitor

Mock vs. ts112
Inhibitor

24
48
72

0.05
0.01
0.12

0.43
0.14
0.67

0.70
0.03
0.30
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Negative
Control vs.
ts-2
Inhibitor
0.00
0.64
0.26

Negative
Control vs.
ts-112
Inhibitor
0.25
0.56
0.94

3.6: MCF10CA1a cell inhibition of ts-2 or ts-112 with Ambion mirVana inhibitors
does not change cell migration
A characteristic of aggressive cancer is its ability to migrate to and invade
surrounding tissue. After observing cell proliferation of MCF10CA1a cells with ts-2 or
ts-112 inhibition, we focused on the migratory and invasive ability of these cells. Here,
we expected ts-2 or ts-112 inhibited populations to migrate less than the mock
populations, since our hypothesis is that these molecules promote cancer phenotypes. To
assess the migratory ability of MCF10CA1a cells after inhibition of tsRNA molecules of
interest, 25 nM Ambion mirVana inhibitors of ts-2 or ts-112 were transfected into the
cells for 4 hours using Lipofectamine 3000. Cells (5x104 cells/well) in serum free media
were plated into migration (control) chambers of a transwell plate and allowed to migrate
through the membrane to the bottom chamber containing full media for 24 hours. At the
appropriate time point, cells were fixed with ethanol and stained with crystal violet for
imaging.
Our results were unexpected. To reiterate, if the central hypothesis that ts-2 or ts112 promote cancer phenotypes, inhibition either of these molecules would lead to a
decrease in migration compared to the mock and negative control populations. Instead, all
of our groups, including the ts-2 or ts-112 inhibited population groups did not show any
migration (Figure 3.6). Images were taken on a inverted microscope at 3.5x to allow
visualization of the entire well. If cells are migratory, they would appear more purple in
the images, as more cells have migrated through the pores of the plate into the full serum
media.
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Figure 3.6: Ts-2 or ts-112 inhibition in MCF10CA1a cells does not effect cell
migration.
Cell migration was assessed using control (no matrigel lining) inserts in a trans-well
assay. Pictures depict the bottom of both the inserts (top column) and wells (bottom
column) after allowing cell poplations to migrate for 24 hours. No cells migrated from
the well inserts into the well bottoms, indicating no migration of MCF10CA1a, no matter
the tsRNA content.
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Due to the shutdown of UVM laboratories, this experiment was only performed once (n =
1). It is important to repeat this experiment in attempt to gain a better understanding of
how manipulation of ts-2 or ts-112 levels in MCF10CA1a cells effects cell motility.
These cells were fixed and stained with crystal violet, but perhaps an assay involving
florescence would allow for better visualization of any potental migration occuring.
Aim 2: Determine the ability of ts-2 or ts-112 to promote breast cancer development
in the normal mammary epithelium
We assessed cell growth, cell death, and the migratory abilities of MCF10A cells
that have been transfected with mimics to overexpress ts-2 or ts-112. This approach
allowed us to investigate the role of tsRNA molecules in promoting breast cancer
phenotypes, in order to determine if tsRNAs are involved in breast cancer development or
initiation. These experiments were done using the same assays performed in
MCF10CA1a cells (Aim 1).
3.7: Ambion mirVana mimic overexpression of ts-2 or ts-112 may increase growth
rate of MCF10A cells
To further investigate the role of ts-2 or ts-112 in regulating cancer cell
growth, normal-like breast epithelial MCF10A cells were transfected with tsRNA
mimics. Ambion mirVana double-stranded RNA molecules designed to specifically
overexpress ts-2 or ts-112 were transfected into the MCF10A cells using the
Lipofectamine 3000 transfection reagent. These experiments were performed as
described for tsRNA inhibition in MCF10CA1a cells. Control groups were a mock (no
nucleic acid) and a negative control transfection. Test groups were transfected with 25
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nM mimics of ts-2 or ts-112. Viable cells (5x106) were plated in 100 mm plastic tissue
culture dishes and transfected with either mock, negative control, ts-2 mimic, or ts-112
mimic for 24-hours. After transfection incubation, cells were plated in triplicate per
condition at 5x104 cells/well in 6-well plates. Cells were counted 24, 48, and 72 hours
after plating using trypan blue exclusion.
This experiment was performed in three independent experiments, in triplicate
(n=3). We expected the results from this experiment to supplement the results from the
growth curve experiments in Aim 1. There, MCF10CA1a inhibition of ts-2 or ts-112 led
to decreased growth rate over time. Here, we expect MCF10A overexpression of ts-2 or
ts-112 to have an increase in growth rate. Instead, there is no statistical difference
between mock and ts-2 or ts-112 inhibited populations (Figure 3.7, Tables 3.19 – 3.21).
Error bars are large due to inconsistencies between replicates, and results reflecting the
expected increase in cell growth are likely if this experiment were repeated.
3.8: CCK-8 assay with Ambion mirVana mimics show an apparent increase
in growth of the ts-2 or ts-112 overexpressed popuations
Cell counting kit-8 (CCK-8) assay for cell proliferation was performed on
MCF10A cells to allow for greater understanding of the role of ts-2 or ts-112 in breast
cells. MCF101A cells were transfected, using Lipofectamine 3000, with 25 nM Ambion
mirVana mimics. Groups for this experiment were mock (no nucleic acid), negative
control, or populations transfected with mimics of either ts-2 or ts-112 for
overexpression. Transfection incubation lasted 4 hours and the experiment followed
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Figure 3.7: Overexpression of ts-2 or ts-112 in MCF10A cells with mirVana mimics
may decrease cell growth rate.
Live cell (phase bright, trypan blue excluding) numbers were determined at 24-hour
intervals for 72 hours following ts-2 or ts-112 overexpression using Ambion mirVana
double-stranded oligonucleotide mimics. Ts-112 mimic populations appear to have a
decrease in growth rate, especially between 48- and 72-hours after plating, although there
are no significant differences between control and mimic populations. Error bars
represent the SEM of 3 independent experiments performed in triplicate.
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Table 3.19: Live Cell Counts
Time
Mock
Expt. 1
Expt. 2
0
50,000
50,000
24
36,367
28,933
48
182,333
141,000
72
985,667
510,233
Time
(Hours)
0
24
48

Expt. 1
50,000
34,000

Ts-2 Mimic
Expt. 2
50,000
5,575

Expt. 3
50,000
1,410
38,333
271,667
Expt. 3
50,000
7,625

Expt. 1
50,000
17,193
134,967
893,333

Negative Control
Expt. 2
Expt. 3
50,000
50,000
16,627
5,245
97,967
179,333
355,667
904,333

Expt. 1
50,000
14,650

Ts-112 Mimic
Expt. 2
Expt. 3
50,000
50,000
1,758
2,053

88,850
91,733
161,667
70,450
78,200
4,985
72
508,333
662,000
1,806,000 730,333
541,667
54,733
Cell counts were generated using trypan blue exclusion on a Life Technologies Countess
II FL machine 24, 48, and 72 hours from plating 50,000 live cells. Reported cell count
values are experiment mean of triplicate wells.
Table 3.20: Mean and Standard Error of the Mean
Time
Mock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
50,000
0
50,000
0
24
22,237
10,632
13,022
3,892
48
120,555
42,807
137,422
23,521
72
589,189
209,861
717,778
181,083
Time
Ts-2 Mimic
Ts-112 Mimic
(Hours)
Mean
SEM
Mean
SEM
0
50,000
0
50,000
0
24
15,733
9,152
6,154
4,249
48
114,083
23,806
51,212
23,221
72
992,111
409,355
442,244
201,265
Mean and SEM of 3 independent experiments performed in triplicate.
Table 3.21: Two-tailed, homoscedastic t-test
Time
Mock vs.
Mock vs. ts- Mock vs. tsNegative
Negative
(Hours)
Negative
2 Mimic
112 Mimic
Control vs.
Control vs.
Control
ts-2 Mimic
ts-112
Mimic
24
0.461
0.667
0.233
0.799
0.299
48
0.747
0.901
0.228
0.524
0.0560†
72
0.667
0.431
0.640
0.573
0.366
† p < 0.1
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the same methods as the CCK-8 assays performed in Aim 1. After transfection
incubation, cells were plated at 5x103 cells/well density in 96-well plates in triplicate per
condition. At appropriate time points after plating (0-hours, 24-hours, 48-hours, and 72hours), WST-8 tetrazolium salt reagent was added to each well for 3 hours and cell
proliferation was assessed on a Victor X4 plate reader at absorbance 450 nm. Numbers
reported below (Tables 3.22-3.24) have been normalized to eliminate background and
represent averages of triplicate wells per experiment. Mean and SEM have been reported
and used to generate the graph. Two tailed, homoscedastic t-tests were performed to
generate statistical analysis of this data. Despite not reaching a statistical difference, the
ts-2 or ts-112 overexpressed populations appear to have an increase in proliferation rate
compared to the mock and negative control populations (Figure 3.8). At the 72-hour time
point, the mean absorbance value of the mock population is 1.381 while the ts-2 or ts-112
overexpressed absorbance values are 1.650 and 1.601 respectively. Here, we see the
expected trend where there is an apparent increase in growth rate in the tsRNA
overexpressed populations compared to the mock and negative controls. These results are
complementary to our central hypothesis that ts-2 and ts-112 promote cancer
phenotypes.
3.9: Overexpression of ts-2 or ts-112 in MCF10A cells has no effect on cell migration
and invasion
To assess the migratory ability of MCF10A cells after overexpression of tsRNA
molecules of interes t, 25 nM Ambion mirVana mimics of ts-2 or ts-112 were transfected
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Figure 3.8: Ts-2 or ts-112 overexpression in MCF10A cells results in an apparent
trend of increased cell proliferation compared to control groups.
Following a 4-hour transfection of ts-2 or ts-112 mimics, MCF10A cells were plated at
equal density and CCK-8 cell proliferation assay performed by measuring absorbance at
450 nm following the addition of an electron mediator, tetrazolium salt (WST-8).
Absorbance values are related to viable cell counts. It appears that the ts-2 or ts-112
mimic populations have an increased number of viable cells compared to the control
populations, although there are no significant values when test groups are compared to
control groups. Error bars represent the SEM of 3 independent experiments performed in
triplicate.
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Table 3.22: Absorbance (OD 450 nm)
Time
Mock
Negative Control
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
-0.005
0.049
0.033
-0.001
0.031
0.070
24
0.018
0.284
0.238
0.073
0.222
0.416
48
0.184
1.032
0.837
0.295
0.765
1.387
72
0.582
1.414
1.757
0.855
1.478
1.895
Time
Mock
Negative Control
(Hours)
Expt. 1
Expt. 2
Expt. 3
Expt. 1
Expt. 2
Expt. 3
0
0.017
0.050
0.062
0.025
0.059
0.113
24
0.216
0.340
0.393
0.194
0.340
0.770
48
0.728
1.138
1.388
0.701
1.153
1.790
72
1.607
1.417
1.963
1.523
1.411
2.071
Absorbance values read at OD 450 nm have been normalized to wells with only media
and WST-8 to eliminate background. Values reported represent the background
corrected mean of triplicate wells per experiment.
Table 3.23: Mean and Standard Error of the Mean
Time
Mock
Negative Control
(Hours)
Mean
SEM
Mean
SEM
0
0.026
0.016
0.033
0.021
24
0.180
0.082
0.237
0.099
48
0.684
0.256
0.816
0.316
72
1.251
0.349
1.409
0.302
Time
Ts-2 Mimic
Ts-112 Mimic
(Hours)
Mean
SEM
Mean
SEM
0
0.043
0.013
0.066
0.026
24
0.316
0.052
0.435
0.173
48
1.085
0.192
1.215
0.316
72
1.662
0.160
1.668
0.204
Mean and SEM of 3 independent experiments performed in triplicates.
Table 3.24: Two-tailed, homoscedastic t-test
Time
Mock vs.
Mock vs. ts- Mock vs. ts(Hours)
Negative
2 Mimic
112 Mimic
Control
0
24
48
72

0.783
0.681
0.763
0.749

0.454
0.234
0.280
0.344

0.256
0.254
0.262
0.360

48

Negative
Control vs.
ts-2 Mimic
0.714
0.519
0.508
0.500

Negative
Control vs.
ts-112
Mimic
0.380
0.378
0.422
0.517

into the cells for 4 hours using Lipofectamine 3000. Cells (50,000 cells/well) in serum
free media were plated into migration (control) chambers and invasion (matrigel)
chambers of a transwell plate and allowed to migrate to through the membrane into full
media for 24 hours. At the appropriate time point, cells were fixed and stained for
imaging. Here, in the migration model, there appears to be no movement of cells from the
inserts with no serum to the wells with full serum media (Figure 3.9). There does appear
to be a slight increase in the invasive ability of MCF10A cells after overexpression of ts112 (Figure 3.9). As these cells are normal-like, these results make sense for the mock
and negative control population. However, if tsRNA overexpression is supposed to
increase cancer characteristics of these cells, it would be expected that invasion and
migration in the ts-2 or ts-112 overexpressed populations would increase, which was the
case only for the ts-112 population in the invasion plates. These results increase our
confidence that ts-112 is related to promoting cancer phenotypes.
3.10 Results Discussion:
Cell Growth
The first characteristic of cancer cells that we investigated is the ability to
proliferate indefinitely, despite the presence of growth inhibitors. If our central
hypothesis is true, that either ts-2 or ts-112 regulate cell growth to promote tumor cell
aggressiveness, inhibition of ts-2 or ts-112 would lead to a decrease in MCF10CA1a cell
growth over time. In our trypan blue exclusion growth curve, MCF10CA1a cells were
transfected with various ts-2 or ts-112 inhibitors and allowed to grow over a 72-hour time
course.
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A.

B.

Figure 3.9 Ts-2 or ts-112 overexpression of MCF10A cells has no effect on cell
migration or invasion.
A. Cell migration was assessed using control inserts in a trans-well assay. Pictures depict
cells after 24 hour migration. No cells migrated from the well inserts into the well
bottoms, indicating no migration of MCF10A cells, no matter the tsRNA content (n=1).
B. Cell invasion was assessed using matrigel lined inserts in a trans-well assay. Pictures
depict cells after 24 hour invasion. Ts-112 overexpressed cells appear to invade more
compared to mock and negative control (n=1).
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With Dharmacon miRIDIAN, custom hairpin inhibitors of the two tsRNA
molecules of interest, population growth appeared to decrease over time (Figure 3.1).
While the decrease in population growth over time did not reach a significant level, the
growth rate did decrease, especially between the 48- and 72-hour time points. The cell
number of the ts-2 inhibited population is on average 22.6% less than that of the mock
population at 72-hours (Table 3.2). The cell number of the ts-112 inhibited population is
on average 17.6% less than that of the mock population at 72-hours (Table 3.2). There is
a suggestive decrease (p<0.093) in population growth at 24-hours for the ts-112 inhibited
population (Table 3.3) that indicates that the inhibition of ts-112 slows population growth
rate within the first two doublings of the cells. The decreased population growth is
sustained throughout the 72-hours (with decreased rates most prominent between 48- and
72-hours) indicating that the inhibition of ts-2 or ts-112 lasts after multiple cell divisions.
These data, though significance was not reached, suggest agreement with our central
hypothesis that ts-2 or ts-112 promote breast cancer disease progression. It is also
important to note that this experiment was performed in similar fashion by previous
members of our lab, who observed similar results.
In contrast, when the same trypan blue exclusion growth curve experiments were
performed using the antisense oligonucleotide, Ambion mirVana inhibitors, there was no
apparent difference in population growth over time in the ts-2 or ts-112 inhibited
populations compared to the control groups (Figure 3.2). Differences in the Dhamacon
miRIDIAN and Ambion mirVana inhibitor mechanisms of action could explain why
these assays portray different results. Further, during transfections, miscalculations led to
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using only half the concentration of Ambion mirVana inhibitors (25 nM) compared to
Dharmacon miRIDIAN inhibitors (50 nM), which could also explain why our
observation of decreased population growth vanished with mirVana inhibitors.
To increase our confidence that ts-2 or ts-112 play a role in regulating population
growth rate over time, the cell counting kit-8 assay was performed using the same
inhibitors used in the trypan blue exclusion assays. Here, absorbance values read on a
plate reader are correlated to cell proliferation; a higher absorbance reading indicates
more cells in the population. With the Dhamacon miRIDIAN custom hairpin inhibitors,
absorbance values were about the same for all test groups throughout all time periods
(Figure 3.3). There is a suggestive (p<0.1) decrease in absorbance in the ts-112
population at 72-hours (Table 3.9). With the Ambion mirVana antisense oligonucleotide
inhibitors, however, there is a significant decrease (p<0.05) in proliferation in the ts-112
inhibited population at the 48- and 72- hour time points when compared to the mock
population (Figure 3.4, Table 3.12). Decrease in absorbance readings throughout the 72hour time course indicates that the tsRNA inhibition lasts beyond a few population
doublings. These CCK-8 assays depicting a decrease in population proliferation rates
over time agree with our central hypothesis that ts-2 or ts-112 regulate cell growth to
promote cancer characteristics. These results suggest that tsRNAs, especially ts-112,
promote cancer cell growth.
If our central hypothesis is true, and ts-2 or ts-112 regulate cell growth to promote
aggressive breast cancer disease progression, overexpression of ts-2 or ts-112 would lead
to an increase in growth in the MCF10A cells. In our trypan blue exclusion growth curve,
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MCF10A cells were transfected with 25 nM Ambion mirVana oligonucleotide mimics of
ts-2 or ts-112 and allowed to grow over a 72-hour time course. With Ambion mirVana
oligonucleotide mimics of the two tsRNA molecules of interest, population growth
appeared to decrease over time (Figure 3.7). Changes in population growth over time
between the groups did not reach significance, however. Repeating this experiment in
attempt to limit the error is important to better understand the results of this assay.
In parallel with our first aim and to increase our confidence that ts-2 or ts-112
play a role in regulating population growth rate over time, the cell counting kit-8 assay
was performed using the same mimics used in the trypan blue exclusion assays. Here,
absorbance values read on a plate reader are correlated to cell proliferation; a higher
absorbance reading indicates more cells in the population. With Ambion mirVana
oligonucleotide mimics of ts-2 or ts-112, absorbance values appear to increase compared
to the control populations (Figure 3.8). Although the differences in absorbance readings
did not reach significance, the ts-2 overexpressed population has an average absorbance
that is 16.4% higher than the mock at 72-hours (Table 3.21). Similarly, the ts-112
overexpressed population has an average absorbance that is 13.8% less than the mock at
72-hours (Table 3.21). The CCK-8 assays depicting an increase in population
proliferation rates over time agree with our central hypothesis that ts-2 or ts-112 regulate
cell growth to promote cancer characteristics. These results suggest that tsRNAs promote
cancer cell growth.
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Cell Cycle Regulation
After observing an increase in cell growth and proliferation with the trypan blue
exclusion growth curves and CCK-8 assays following ts-2 or ts-112 inhibition of
MCF10CA1a cells, we questioned if this was due to tsRNAs playing a role in cell cycle
regulation. After a 24-hour transfection with Dharmacon miRIDIAN inhibitors of ts-2 or
ts-112, the cell cycle of MCF10CA1a cells was analyzed using flow cytometry. Here, we
observed an increase in S phase and a decrease in G1 phase of cells following ts-2 or ts112 inhibition compared to the mock and negative control populations. This indicates that
cells are dividing less, spending more time in S phase, which is responsible for DNA
replication in preparation for mitosis. Through this experiment, we understood more
clearly that ts-2 or ts-112 play a role in increasing population doubling time, by
increasing up the amount of time cells spend in S phase.
Cell Death
In order to understand if ts-2 or ts-112 are involved in regulating cancer cell
death, cell death percentages generated from the trypan blue exclusion growth curve were
analyzed and compared between groups over a 72-hour time course. Cancer cells can
ignore apoptosis signals and continue to grow. If ts-2 or ts-112 promote cancer cell
characteristics, it would be expected that there would be an increase in cell death when ts2 or ts-112 are inhibited in MCF10CA1a cells. This was not the case. There is no change
in cell death between the tsRNA inhibited populations when compared to the control
populations. Ts-2 or ts-112 molecules may promote cancer phenotypes by increasing
population doubling time (seen in cell cycle analysis) and increasing proliferation rate
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(seen in growth curves and CCK-8 assays), but these molecules are not involved in
evading cell death.
Cell Migration and Invasion
Cancer cells can migrate to a location in the body where they did not originate.
This migratory capability is known as metastasis and is a characteristic of aggressive,
stage IV cancer types. To further understand the role of ts-2 or ts-112 in aggressive breast
cancer, MCF10CA1a cells were transfected with Ambion mirVana antisense
oligonucleotide inhibitors of ts-2 or ts-112 and plated in a trans-well plate to assess
migration. Results of our trans-well assay for cell migration did not reflect our
expectations. Since cancer cells can migrate and metastasize, we expected the mock and
negative control populations to migrate. If ts-2 or ts-112 are supposed to promote cancer
cell characteristics, then the inhibited populations would show a decrease in cell
migration compared to the mock and control. However, there was no changes in cell
migration in our ts-2 or ts-112 inhibited populations compared to the control groups
(Figure 3.6). Although this experiment was only performed once (n=1), it could be
assumed that ts-2 or ts-112 have no effect on cancer cells ability to migrate. These results
do not support our central hypothesis that ts-2 or ts-112 promote cancer characteristics.
To keep our experiments consistent between the two aims of the project, we
evaluated the ability of MCF10A cells to migrate in a trans-well assay following ts-2 or
ts-112 overexpression. MCF10A cells were transfected with Ambion mirVana
oligonucleotide mimics of ts-2 or ts-112 and plated in a trans-well plate to assess
migration. Results of our trans-well assay for cell migration again did not reflect our
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expectations. Since cancer cells can migrate and metastasize more easily than normal like
cells, we expected the mock and negative control populations to remain in low serum
media, without migrating into full serum media. If ts-2 or ts-112 are said to promote
cancer cell characteristics, then the overexpressed populations would show an increase in
cell migration compared to the mock and control. However, there was no changes in cell
migration in our ts-2 or ts-112 inhibited populations compared to the control groups
(Figure 3.10A). Although this experiment was only performed once (n=1), it could be
assumed that ts-2 or ts-112 have no effect on cancer cells ability to migrate. An invasion
assay, involving a Matrigel-lined trans-well insert was also performed. This experiment
resulted in an increase in cell invasion in the ts-112 overexpressed group (Figure 3.9B).
These results do support our central hypothesis that ts-112 promotes cancer
characteristics.
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CHAPTER 4: DISCUSSION
4.1 Background and Project Overview
In the United States, 1 in 8 women will be diagnosed with breast cancer at some
point in her life (1). The five-year survival rate of stage IV disease remains less than 30%
(1, 2). There remains a need for a better understanding of the molecular mechanisms
driving stage IV disease to improve the overall survival rates of patients diagnosed with
aggressive breast cancer. It has been recently discovered that tRNA-derived small RNA
(tsRNA) molecules are dysregulated in breast cancer. To elucidate the molecular
mechanisms driving breast cancer, the Stein/Lian research group profiled 113 established
tsRNAs in MCF10A, MCF10AT1, MCF7, MCF10CA1a, and MDA-MB-231 cell lines
and H9 female human embryonic stem cells (hESC). Two tsRNAs, ts-2 and ts-112, have
relatively low levels in the normal-like, mammary epithelial MCF10A cells and high
levels in MCF10CA1a and MDA-MB-231 aggressive breast cancer cell lines (3). Further,
H9 hESCs express high levels of ts-2 and ts-112. Studies have identified many genes
highly expressed in hESCs to be upregulated in cancer cells (3). For this reason, ts-2 and
ts-112 were chosen for our studies.
The central hypothesis of this project stated that ts-2 and ts-112 regulate cell
growth, death, migration, and the invasive ability to promote breast cancer progression to
aggressive disease. We tested our hypothesis in Aim 1, identify the functions of ts-2 and
ts-112 in aggressive breast cancer, by inhibiting ts-2 and ts-112 in the MCF10CA1a
aggressive breast cancer cell line. In Aim 2, determine the ability of ts-2 and ts-112 to
promote breast cancer characteristics in the normal mammary epithelium, we
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overexpressed ts-2 and ts-112 with mimics in the MCF10A normal-like mammary
epithelial cell line. Here, we will address the results in relation to the central hypothesis,
in attempt to understand how tsRNA molecules regulate cancer progression. With
successful completion of this project, we now have a greater understanding of tsRNA
molecules and their roles in driving aggressive breast cancer. Our findings, supporting
our hypothesis or not, have a positive impact in the search to identify new molecular
targets for precision treatment approaches against aggressive breast cancer.
To identify the functions of ts-2 and ts-112 in aggressive breast cancer (Aim 1),
experiments were performed in the MCF10CA1a cell line to inhibit ts-2 and ts-112.
MCF10CA1a cells are representative of aggressive breast cancer and ts-2 and ts-112
levels are highly expressed in this cell type compared to both normal-like breast cells and
cells representative of stage I-III breast cancer (3). Here, we compared different custom
ts-2 or ts-112 inhibitors with unique mechanisms of action that were purchased from two
different companies. Dharmacon miRIDIAN inhibitors were designed to be singlestranded RNA molecules with complementary sequences to ts-2 or ts-112, with both 5’
and 3’ RNA hairpin structures. Ambion mirVana inhibitors were designed as single
stranded RNA molecules complementary to ts-2 or ts-112 with modified RNA bases for
stability. To determine the ability of ts-2 or ts-112 to promote breast cancer
characteristics in the normal mammary epithelium (Aim 2), experiments were performed
in the MCF10A cell line following overexpression of ts-2 or ts-112. MCF10A cells are
representative of cells in the normal mammary epithelium and ts-2 and ts-112 levels are
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low in these cells. Here, we used custom Ambion mirVana mimics to overexpress ts-2 or
ts-112.
We assessed population cell growth/death using both trypan blue exclusion and
the Cell Counting Kit-8 (CCK-8) assay and observed that tsRNA levels alter growth rate
to promote cancer characteristics. Further evidence that ts-2 and ts-112 promote cancer
characteristics was shown via an increase in population percentage in S phase and a
decrease in population percentage in G1 phase following ts-2 or ts-112 inhibition of
MCF10CA1a cells assessed using flow cytometry. In addition, we investigated cell
migration and invasion using trans-well assays, but there was little evidence that ts-2 or
ts-112 manipulation results in any migration/invasion activity of MCF10A or
MCF10CA1a cells.
4.2 TsRNAs responsive to tumor suppressors could explain changes in cell cycle
Thu, et al, 2018, describes changes in the cell cycle in breast cancer cells (4).
Transitions through the cell cycle from one phase to another are dependent on satisfying
checkpoints. One way that cancer cells grow uncontrollably is by evading the
checkpoints and progressing through the cycle anyway. Targeting the cell cycle is an
important technique in treating breast cancer.
A recent publication from the Stein/Lian research group, Farina et. al, 2020,
established a connection between runt-related transcription factor-1 (RUNX1) and
tsRNAs (5). The paper identified four tsRNA molecules, including ts-112, that were
responsive to the tumor suppressor, RUNX1, in breast cancer. RUNX1 is a key
transcription factor in breast cancer initiation and progression. There is evidence that this
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tumor suppressor maintains the mammary epithelium by regulating tsRNA expression
levels. The authors concluded that ts-112 is oncogenic, and RUNX1 acts as a tumor
suppressor by inhibiting ts-112 to maintain the mammary epithelium.
Although RUNX1 was the only transcription factor reported in the publication to
have a regulatory capacity on tsRNA molecules, it is not to say that other transcription
factors don’t also interrupt or promote tsRNA activity. Tumor protein p53 is a tumor
suppressor involved in regulating the cell cycle at the G1/S checkpoint. DNA damage
leads to increased expression of the p53 gene, which acts to prevent the cell from entering
the S phase of the cell cycle to allow time for DNA repair. P53 mutations are common in
breast cancer, and many other types of cancer (6).

Figure 4.1: TsRNAs may interrupt the binding between p53 and mdm2
Data from our cell proliferation and cell cycle assays provide evidence that results
from tsRNA manipulation could be linked to p53 involvement. The ubiquitin ligase
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protein, mdm2, is responsible for binding to and inhibiting p53 activity in healthy cells. It
is possible that ts-2 or ts-112 have a role in degrading p53, therefore allowing for the cell
cycle to continue. To test this theory, studies could be performed to evaluate the integrity
of p53/mdm2 binding in the presence or absence of ts-2 or ts-112. Future studies
involving tsRNA molecules and various tumor suppressor molecules are important in
order to understand the role of tsRNAs in the molecular mechanisms driving aggressive
breast cancer.
Our data indicated a potential increase in S phase and a decrease in G1 phase in
the cell population following ts-2 or ts-112 inhibition of MCF10CA1a cells. This
indicates the potential ability if cells to ignore G1/S checkpoint proteins. E2F is a group
of genes upstream of p53 that encodes proteins responsible for the transition from the G1
phase to S phase. It is possible that ts-2 and ts-112 are responsible for repressing E2F
activity, and thus inhibition of ts-2 or ts-112 leads to an increased percentage of cells
entering the S phase.
4.3 TsRNAs potential involvement in cancer diagnosis and treatment
In Balatti, et. al, 2017, the authors study various tsRNA molecules involved in
different cancer types (3). Their experiments provide evidence that tsRNAs are involved
in different stages of cancer progression. While some tsRNAs (ex. ts-36 in colon cells)
are not expressed in adenomas, they are upregulated in carcinomas, suggesting that they
are involved in the progression of benign tumors into malignant ones (3). Like in Farina
et. al, 2019, experiments involving various tumor suppressors were shown to manipulate
tsRNA expression levels.
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Our data provide evidence ts-2 and ts-112 are upregulated in cancer cell models
compared to the normal like cell line MCF10A. MCF10CA1a aggressive breast cancer
cells grow slower when ts-2 or ts-112 are inhibited, indicating that tsRNA inhibitors
could potentially be used as targeted treatment of some cancers to decrease disease
progression over time. These data are supportive of the idea that future diagnosis
strategies and treatment therapies could take advantage of this active crosstalk between
tsRNAs and oncogenes.
4.4 Conclusions and Future Directions
Based on the results of the experiments performed, the main conclusion of this
project is the ts-112 is oncogenic and promotes cell proliferation. In our cell growth
experiments, ts-112-inhibited MCF10CA1a populations showed a decrease in cell growth
rate over time and ts-112-overexpressed MCF10A populations showed an increase in cell
growth rate over time. To improve this project, studies in the future could evaluate the
role of ts-112 on regulating cell cycle checkpoint genes. Perhaps the change in the cell
cycle seen in ts-112-inhibited MCF10CA1a populations could be explained by ts-112
altering mechanisms of checkpoint genes, allowing the cells to continue to grow and
divide (seen with an increase in S phase). Furthermore, studies to determine tsRNA
binding partners is important when discussing the future of this project. Both
computational predictions of RNA:RNA interactions as well as RNA
immunoprecipitation for potential involvement in RNA-induced silencing complex
(RISC) could help further explain the role of tsRNAs in promoting cancer phenotypes.
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TsRNA research is still new. Not many groups have published work on these
molecules. Once there is a greater understanding of ts-2, ts-112, and tsRNAs in general,
we are hopeful that there will be a greater understanding of the molecular mechanisms
driving aggressive breast cancers. It is important to understand these molecular
mechanisms in order to someday increase the 5-year survival prognosis for individuals
diagnosed with metastatic breast cancer.
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